(IN BRIEF) Novartis announced positive Phase III results from the RemIND trial showing that the oral BTK inhibitor remibrutinib achieved significantly higher complete response rates than placebo in three major forms of chronic inducible urticaria. The treatment demonstrated good tolerability … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Angelika Jahreis, autoimmune and inflammatory diseases, BTK inhibitor, chronic inducible urticaria, chronic urticaria treatment, CIndU, dermatology innovation, FDA application, global clinical trials, histamine pathway, immunology research, Novartis, Novartis Advances Immunology Pipeline with Promising Late Stage Outcomes for Oral BTK Inhibitor in Rarely Addressed Skin Disorder, Phase III study, regulatory submission, remibrutinib, RemIND trial, Rhapsido, targeted therapy development
(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release
TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?